You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)附屬開發抗血栓藥獲頒藥品註冊批件
阿思達克 07-04 12:10

中國生物製藥(01177.HK)公布,附屬公司南京正大天晴製藥有限公司開發的抗血栓藥「替格瑞洛片」已獲得國家藥品監督管理局頒發藥品註冊批件。

替格瑞洛是一種新型抗血栓藥,通過可逆性結合到血小板P2Y12 ADP受體,阻斷血小板活化,用於急性冠脈綜合症患者,減少血栓性心血管事件的發生。

集團的替格瑞洛片,是按照仿製藥質量與療效一致性評價標準開發,已完成全部藥學和生物等效一致性研究,被視同通過一致性評價。公司指,產品獲批上市有助集團持續積極開發多元化產品,進一步豐富產品線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account